I got the feeling from the Cohen call that they're MNTA trials, and they're bio-equivelence trials, not efficacy/safety. Whether Mylan does some too I don't think will carry any weight, since i'm pretty sure these are MNTA's and CW reiterated emphatically they're still on the j pathway and he hasn't seen anything to make him think otherwise.
Market Data 
Markets 
AI
